Scholar Rock Holding (SRRK) Non-cash Items (2018 - 2026)
Scholar Rock Holding's quarterly Non-cash Items came in at $204.9 million in Q1 2026, up 37.05% year-on-year from $149.5 million in Q1 2025, and up 10.47% quarter-over-quarter from $185.5 million in Q4 2025.
Scholar Rock Holding has reported Non-cash Items for 9 years, with the latest figure at $204.9 million in Q1 2026.
- For the quarter ending Q1 2026, Non-cash Items rose 37.05% year-over-year to $204.9 million; the trailing twelve-month figure through Mar 2026 stood at $204.9 million (up 37.05% YoY), and the FY2025 full-year result was $4.1 million, down 98.31% from the prior year.
- Non-cash Items for Q1 2026 stood at $204.9 million, up from $185.5 million in the prior quarter.
- The five-year high for Non-cash Items was $244.7 million in Q4 2024, with the low at $748000.0 in Q2 2022.
- Average Non-cash Items over 5 years is $63.1 million, with a median of $4.8 million recorded in 2024.
- Year-over-year, Non-cash Items sank 98.52% in 2022 and surged 4296.03% in 2025.
- Tracing SRRK's Non-cash Items over 5 years: stood at $5.8 million in 2022, then surged by 796.3% to $52.3 million in 2023, then surged by 367.84% to $244.7 million in 2024, then declined by 24.18% to $185.5 million in 2025, then climbed by 10.47% to $204.9 million in 2026.
- The last three Non-cash Items figures came in at $204.9 million (Q1 2026), $185.5 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 204.95 Mn |
| Mar 31, 2026 | 204.95 Mn |
| Dec 31, 2025 | 185.53 Mn |
| Dec 31, 2025 | 185.53 Mn |
| Sep 30, 2025 | 4.52 Mn |
| Sep 30, 2025 | 4.52 Mn |
| Jun 30, 2025 | 155.14 Mn |
| Jun 30, 2025 | 155.14 Mn |
| Mar 31, 2025 | 149.54 Mn |
| Mar 31, 2025 | 149.54 Mn |
| Dec 31, 2024 | 244.68 Mn |
| Dec 31, 2024 | 244.68 Mn |
| Sep 30, 2024 | 4.83 Mn |
| Sep 30, 2024 | 4.83 Mn |
| Jun 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | 3.53 Mn |
| Mar 31, 2024 | 49.13 Mn |
| Mar 31, 2024 | 49.13 Mn |
| Dec 31, 2023 | 52.30 Mn |
| Dec 31, 2023 | 52.30 Mn |
| Sep 30, 2023 | 2.33 Mn |
| Sep 30, 2023 | 2.33 Mn |
| Jun 30, 2023 | 3.14 Mn |
| Jun 30, 2023 | 3.14 Mn |
| Mar 31, 2023 | 2.67 Mn |
| Mar 31, 2023 | 2.67 Mn |
| Dec 31, 2022 | 5.84 Mn |
| Dec 31, 2022 | 5.84 Mn |
| Sep 30, 2022 | 2.25 Mn |
| Sep 30, 2022 | 2.25 Mn |
| Jun 30, 2022 | 748,000.00 |
| Jun 30, 2022 | 748,000.00 |
| Mar 31, 2022 | 1.75 Mn |
| Mar 31, 2022 | 1.75 Mn |
| Dec 31, 2021 | 26.27 Mn |
| Dec 31, 2021 | 26.27 Mn |
| Sep 30, 2021 | 1.43 Mn |
| Sep 30, 2021 | 1.43 Mn |
| Jun 30, 2021 | 1.15 Mn |
| Jun 30, 2021 | 1.15 Mn |
| Mar 31, 2021 | 118.63 Mn |
| Mar 31, 2021 | 118.63 Mn |
| Dec 31, 2020 | 123.60 Mn |
| Dec 31, 2020 | 123.60 Mn |
| Sep 30, 2020 | 1.21 Mn |
| Sep 30, 2020 | 1.21 Mn |
| Jun 30, 2020 | 18.21 Mn |
| Jun 30, 2020 | 18.21 Mn |
| Mar 31, 2020 | 22.90 Mn |
| Mar 31, 2020 | 22.90 Mn |
| Dec 31, 2019 | 6.52 Mn |
| Dec 31, 2019 | 6.52 Mn |
| Sep 30, 2019 | 14.90 Mn |
| Sep 30, 2019 | 14.90 Mn |
| Jun 30, 2019 | 10.57 Mn |
| Jun 30, 2019 | 10.57 Mn |
| Mar 31, 2019 | 318,576.00 |
| Mar 31, 2019 | 318,576.00 |
| Dec 31, 2018 | 19.83 Mn |
| Dec 31, 2018 | 19.83 Mn |
| Sep 30, 2018 | 119,066.00 |
| Sep 30, 2018 | 119,066.00 |
| Jun 30, 2018 | 53,217.00 |
| Jun 30, 2018 | 53,217.00 |